

## Insights into Analysis of Phenolic Secoiridoids in Extra Virgin Olive Oil

Rita Celano, Anna Lisa Piccinelli, Alessandro Pugliese, Sonia Carabetta, Rosa Di Sanzo, Luca Rastrelli, and Mariateresa Russo

*J. Agric. Food Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.8b01751 • Publication Date (Web): 25 May 2018

Downloaded from <http://pubs.acs.org> on May 31, 2018

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1 **Insights into Analysis of Phenolic Secoiridoids in Extra Virgin Olive Oil**

2 Rita Celano<sup>†</sup>, Anna Lisa Piccinelli<sup>†,\*</sup>, Alessandro Pugliese<sup>‡</sup>, Sonia Carabetta<sup>‡</sup>, Rosa di Sanzo<sup>‡</sup>, Luca  
3 Rastrelli<sup>†</sup>, Mariateresa Russo<sup>‡</sup>

4

5 <sup>†</sup> *Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano (SA),*  
6 *Italy*

7 <sup>‡</sup> *Department of Agriculture Science, Food Chemistry, Safety and Sensoromic Laboratory (FoCuSS*  
8 *Lab), University of Reggio Calabria, Via Salita Melissari, 89124, Reggio Calabria, Italy*

9

10 \*Corresponding author. Tel: +39 089969794; Fax; E-mail address: [apiccinelli@unisa.it](mailto:apiccinelli@unisa.it)

11 **ABSTRACT:** Extra virgin olive oils (EVOOs) containing more than 5 mg/20 g of tyrosol,  
12 hydroxytyrosol and their secoiridoids can be recognized with the health claim related to the  
13 protection of blood lipids from oxidative stress. Therefore, a reliable, accurate and standardized  
14 analytical procedure is needed to determine these markers of EVOO quality. In order to overcome  
15 the limitations of current methods, a detailed investigation of sample preparation and  
16 chromatographic conditions was performed by UHPLC-UV-HRMS. The use of C18 fused-core  
17 column and a non-acidified gradient elution provided single sharp peaks for oleocanthal and  
18 oleacein, allowing their reliable quantitation in UV profile. Positive and negative UHPLC-  
19 HRMS/MS characterization of methanolic extracts revealed the presence of dimethyl acetal, methyl  
20 hemiacetal and monohydrate derivatives of all secoiridoids. These artefacts were formed in aqueous  
21 methanol, usually employed to extract and analyse the EVOO phenols, making the HPLC profiles  
22 more complex and the measurements less accurate and reproducible. Acetonitrile proved to be a  
23 suitable solvent to avoid the formation of secoiridoid dimethyl acetals and methyl hemiacetals, and  
24 to efficiently extract EVOO bioactive phenols. Finally, the phenolic contents of Italian EVOO  
25 samples were determined by UHPLC-UV analysis of acetonitrile extracts before (direct method)  
26 and after acid hydrolysis (indirect method). The results indicated that the use of tyrosol and  
27 hydroxytyrosol as reference standards allowed more accurate quantitative data to be obtained.  
28 Direct and indirect methods provided comparable levels of EVOO phenols, highlighting the  
29 usefulness of acid hydrolysis in routine analyses. The improved procedure defines the most reliable  
30 conditions to provide an analytical method with suitable accuracy and repeatability in the analysis  
31 of healthy and functional EVOO phenols.

32

33 **KEYWORDS:** extra virgin olive oil; phenolic secoiridoids; positive and negative-UHPLC-HRMS  
34 analysis; artefacts.

## 35 INTRODUCTION

36 Extra virgin olive oil (EVOO) has nutritional, technological, sensory characteristics and health-  
37 protecting activities that make it a unique ingredient of the Mediterranean diet. These properties are  
38 strictly related to its high content of oleic acid and hydrophilic phenolic compounds.<sup>1-5</sup> In particular,  
39 the EVOO quality is mainly affected by the content of hydroxytyrosol (3,4-dihydroxyphenylethyl  
40 alcohol, 3,4-DHPEA, **1**), tyrosol (4-hydroxyphenethyl alcohol, *p*-HPEA, **2**), and their esterified  
41 derivatives with oleic acid, known as secoiridoids (Figure 1).<sup>1-6</sup> These compounds are the most  
42 complex, abundant and typical family in the EVOO polar fraction.<sup>1-5</sup> The most abundant  
43 secoiridoids in EVOO are the monoaldehydic forms of oleuropein (3,4-DHPEA-EA, **3**) and  
44 ligstroside (*p*-HPEA-EA, **4**) aglycones, and the dialdehydic forms of their decarboxymethylated  
45 derivatives, oleacein (3,4-DHPEA-EDA, **5**) and oleocanthal (*p*-HPEA-EDA, **6**) (Figure 1).<sup>7,8</sup>  
46 Secoiridoids act as the main natural antioxidants of EVOO,<sup>1,9</sup> and they are the main contributors to  
47 EVOO organoleptic characteristics (bitter and pungent attributes).<sup>9</sup> Moreover, they are the most  
48 studied and best-known components in terms of health-protecting activities.<sup>5,10-12</sup> The content of **1**,  
49 **2**, and their secoiridoid derivatives in EVOO have been correlated in humans with the increase in  
50 the antioxidant content of LDL and a nutrigenomic effect, modulating the expression of  
51 atherosclerosis-related genes towards a protective mode.<sup>5,13</sup>  
52 Actually, the regulation EU n.432/2012 permits acknowledgement of the health claim “Olive oil  
53 polyphenols contribute to the protection of blood lipids from oxidative stress” for EVOOs  
54 containing at least 5 mg of hydroxytyrosol and its derivatives (e.g. oleuropein complex and tyrosol)  
55 per 20 g of olive oil.<sup>14</sup> This is a very important tool with a significant impact on the field of olive oil  
56 marketing and labeling. The possibility of adopting a label with the health claim based on the  
57 content of bioactive phenols would be useful to effectively signal both the “healthiest” and the  
58 “highest quality” EVOOs.<sup>15</sup> However, the olive oil industry has not taken advantage of this  
59 opportunity. The main concerns involve the lack of clarity in determining the bioactive compounds  
60 and the analytical protocol to apply the claim.

61 Beyond the phenol content, the determination of phenolic profile (amount and type of the individual  
62 components) of EVOO is of great interest in olive oil manufacturing process, as the phenolic  
63 composition depends on various factors, e.g. olive cultivar and maturity stage, climatic and  
64 agronomic conditions, the pre-processing, processing, and post-processing procedures of EVOO  
65 production.<sup>15</sup> Hence, reliable and accurate analytical methods are needed to characterize the  
66 complex EVOO phenolic pattern, to develop complete compositional databases and to obtain more  
67 accurate intake data of healthy and functional EVOO phenols.

68 Many methods have been developed to characterize the complex phenolic pattern of EVOOs,  
69 mainly based on HPLC separation followed by UV/Vis or mass spectrometry (MS) detection, and  
70 quantitative NMR.<sup>1,2,7,8,16</sup> In 2011, the International Olive Council (IOC) proposed a standard  
71 procedure based on the HPLC-DAD analysis of the methanolic extract where all phenols are  
72 quantitated as *p*-HPEA (**2**) equivalents.<sup>17</sup> However, the determination of EVOO phenols by HPLC  
73 is rather difficult, mainly due to chromatographic resolution (co-elutions, broadened peaks, isomeric  
74 forms of secoiridoids), peak identification problems and to the lack of standards for a reliable  
75 quantitative analysis.<sup>18</sup>

76 In addition, several limitations of HPLC methods in the determination of oleocanthal (**6**) and  
77 oleacein (**5**) have been recently identified.<sup>7,19</sup> These dialdehydic compounds react immediately with  
78 methanol and/or water to give mixtures of hemiacetals or acetals.<sup>7</sup> This interaction can occur during  
79 either extraction and/or chromatographic steps, since these protic solvents are commonly used for  
80 the determination of EVOO phenols. Consequently, some peaks in HPLC-UV or LC-MS  
81 chromatograms may correspond to artefacts produced by that type of reaction, making the HPLC  
82 profiles much more complex and less reproducible. Also, in quantitative methods based on selective  
83 MS/MS fragmentation of aldehydic secoiridoid forms, the hemiacetal and acetal artefacts are not  
84 measured, leading to questionable conclusions about the reliability of such measurements.

85 Based on these complications of current analytical methods and the urgent need to facilitate the  
86 EVOO phenols determination for their potentiality as markers of the EVOO quality, in the present

87 research a comprehensive re-evaluation of EVOO phenolic profile, focusing on secoiridoids, was  
88 performed. To gain insight into secoiridoid characterization, different extraction and  
89 chromatographic conditions were studied by UHPLC-UV-HRMS with negative and positive  
90 electrospray ionization modes. The main aims were therefore: i) to enhance the chromatographic  
91 resolution; ii) to investigate the formation of hemiacetals and acetals from secoiridoids during the  
92 sample preparation; and iii) to define the most reliable conditions to provide an analytical method  
93 with suitable accuracy and repeatability.

94 **MATERIALS AND METHODS**

95

96 **Reagents and Standards.** Analytical-grade methanol (MeOH), acetonitrile (MeCN) *n*-hexane,  
97 caffeine (volumetric internal standard, IS), and MS-grade acetic acid, ammonium formate,  
98 ammonium acetate and formic acid (HCOOH), were obtained from Sigma-Aldrich (Milan, Italy).

99 Ultrapure water (18 M $\Omega$ ) was prepared by a Milli-Q purification system (Millipore, BedfordMA).

100 MS-grade MeCN and water were supplied by Romil (Cambridge, UK).

101 Reference standards ( $\geq$ 98% HPLC grade) of hydroxytyrosol (3,4-DHPEA, **1**), tyrosol (*p*-HPEA, **2**)

102 and pinoresinol were purchased from Extrasynthase (Lyon, France). Oleacein (3,4-DHPEA-EDA,

103 **5**) and oleocanthal (*p*-HPEA-EDA, **6**) were provided by PhytoLab GmbH (Vestenbergsgreuth,

104 Germany). Standard stock solutions of **1** and **2** (1 mg/mL) were prepared in acetonitrile and stored

105 at 4 °C. Diluted solutions and standard mixtures were prepared in MeCN/H<sub>2</sub>O 2:8, v/v.

106

107 **Extra Virgin Olive Oil Samples.** Eleven Italian EVOOs (O1-11) of the season 2016–2017 were

108 collected from supermarkets and Calabrian farmers and stored away from light. Six EVOO samples

109 (O5-10) are protected denomination of origin (PDO) oils from various Italian regions.

110

111 **Isolation of EVOO Phenolic Compounds by Liquid-Liquid Extraction.** EVOO phenolic

112 compounds were extracted following the IOC method,<sup>17</sup> with some modifications. A 1.5 g  $\pm$  0.03

113 aliquot of EVOO sample was weighed in a 15 mL conical tube and extracted with 4.5 mL of

114 MeOH/H<sub>2</sub>O (8:2, v/v) or MeCN/H<sub>2</sub>O (8:2, v/v). The mixture was shaken by electronic shaker for 1

115 min and the extraction was performed with the aid of an ultrasonic bath for 15 min. Then, the two

116 phases were separated by centrifugation at 13000 rpm for 10 min, and the hydrophilic phase was

117 evaporated to dryness under vacuum at 30 °C in a rotary evaporator. The residue was dissolved with

118 1 mL of MeOH/H<sub>2</sub>O (3:7, v/v) or MeCN/H<sub>2</sub>O (2:8, v/v) containing IS (final concentration 10

119  $\mu$ g/mL). *n*-Hexane (1 mL) was added to the solution to wash away any remaining oil. The tube was

120 centrifuged for phase separation, before the chromatographic analysis. Each EVOO sample was  
121 extracted in triplicate.

122

123 **Acid Hydrolysis.** To determine the total amount of free and linked **1** and **2** in EVOO phenolic  
124 extracts, the acid hydrolysis procedure of Mulinacci et al.<sup>20</sup> was used with slight modifications.  
125 Briefly, 200  $\mu$ L of extract was added with 200  $\mu$ L of H<sub>2</sub>SO<sub>4</sub> 1.0 M. The samples were maintained at  
126 80 °C for 2 h in a thermostat, then the reaction was stopped by freezing the tubes in an ice bath.  
127 Finally, the samples were diluted with 200  $\mu$ L of NaOH 2 M, and IS was added at the final  
128 concentration of 10  $\mu$ g/mL before UHPLC-UV analyses. The hydrolysis procedure was carried out  
129 in duplicate for each phenolic extract (triplicates) and then the hydrolysates were combined for  
130 UHPLC-UV analyses.

131 Preliminary experiments were performed to verify the chemical stability of **1** and **2** and the  
132 completeness of the ester linkage hydrolysis (monitoring the hydrolysis of extract up to 4 h by  
133 UHPLC-UV) under hydrolysis conditions.

134

135 **UHPLC-HRMS Analyses.** Chromatographic analyses were performed using a Platin Blue UHPLC  
136 system (Knauer, Labservice Analytica, Bologna, Italy), consisting of two ultra high-pressure  
137 pumps, an autosampler, a column temperature manager, coupled to a LTQ OrbiTrap XL mass  
138 spectrometer (Thermo Fisher Scientific, Milan, Italy). A 100 x 2.1 mm I.D., 2.6  $\mu$ m column,  
139 Kinetex C18, (Phenomenex, Bologna, Italy) was used at a flow rate of 400  $\mu$ L/min and at the  
140 temperature of 25 °C. The mobile phase was a binary gradient of water (A) and MeCN (B). The  
141 gradient elution program is as follows: 0-6 min, 2% B; 6-10 min, 2-23% B; 10-15 min, 23% B; 15-  
142 22, 23-50 % B; 22-27 min, 50-98% B. After each injection (5  $\mu$ L), cleaning (98% B, 6 min) and re-  
143 equilibration of the column (6 min) were performed.

144 The mass spectrometer, equipped with ESI source, was operated in negative and positive ionization  
145 modes. High purity nitrogen (N<sub>2</sub>) was used as sheath gas (50 arbitrary units) and auxiliary gas (25



146 arbitrary units). High purity helium (He) was used as collision gas. Optimized mass spectrometer  
147 parameters in negative ionization mode were as follows: source voltage 2.5 kV, capillary voltage –  
148 25 V, tube lens voltage –110 V. Optimized conditions in positive ionization mode were: source  
149 voltage 3.5 kV, capillary voltage 48 V, tube lens voltage 65 V. In both modes, capillary temperature  
150 was 250 °C. Mass spectra were acquired by full range acquisition covering  $m/z$  130–800. For  
151 fragmentation study, a data dependent scan was performed and the normalized collision energy of  
152 the collision-induced dissociation (CID) cell was set at 35 eV and the isolation width of precursor  
153 ions was set at 2.0. The resolving power was 100000 and 30000 for the full mass and the data  
154 dependent MS scan, respectively. Compounds were characterized according to the corresponding  
155 HRMS spectra, accurate masses, characteristic fragmentations, and retention times. Xcalibur  
156 software (version 2.2) was used for instrument control, data acquisition and data analysis.

157

158 **UHPLC-UV Analyses.** The UHPLC-UV analyses were performed using a Dionex Ultimate 3000  
159 UHPLC system (Thermo Fisher Scientific) constituted of an Ultimate 3000 RS Pump, an Ultimate  
160 3000 RS autosampler, an Ultimate 3000 RS column compartment and Ultimate 3000 RS variable  
161 wavelength detector. The chromatographic conditions were the same as those used for UHPLC–  
162 HRMS analysis, and the UV chromatograms were recorded at 254, 278 and 350 nm. For  
163 quantitative determination of 3,4-DHPEA (**1**) and *p*-HPEA (**2**) and secoiridoids in EVOO phenolic  
164 extracts and hydrolysates, the wavelength of 278 nm was used. **1** and **2** were employed as reference  
165 standards, and six concentration levels were prepared diluting with water appropriate volumes of  
166 stock solutions (1 mg/mL, MeCN). IS was added to each level at the concentration of 10 µg/mL.  
167 Linearity of calibration curves were evaluated in the concentration ranges of 5-200 µg/mL, and  
168 triplicate injections for each level. UV peak area ratios (*p*-HPEA/IS and 3,4-DHPEA/IS) were  
169 plotted against the corresponding standard concentrations (µg/mL).

170 The regression curves were tested with the analysis of variance (ANOVA) and linear model was  
171 found appropriate over the tested concentration ranges (**1**,  $y = 0.0166 x - 0.1130$ ;  $R^2 = 0.9991$ ; **2**,  $y$

172 =  $0.0204x - 0.023$ ;  $R^2 = 0.9993$ ). For reference compounds (**1** and **2**), the limits of detection (LOD)  
173 and of quantification (LOQ) were calculated by extrapolation of the concentrations giving a signal-  
174 to-noise ratio (S/N) of 3 and 10, respectively, from a linear regression (S/N versus concentration):  
175 for **1**, LOD = 0.5  $\mu\text{g/mL}$  and LOQ = 1.0  $\mu\text{g/mL}$ ; for **2**, LOD = 1.4  $\mu\text{g/mL}$  and LOQ = 2.5  $\mu\text{g/mL}$ .  
176 The accuracy of the LLE methods (aqueous methanol and acetonitrile) was estimated by recovery  
177 experiments, adding known amounts of **1** and **2** to a seed oil sample that did not contain the  
178 molecules studied. Both LLE solvents showed exhaustive extraction of **1** and **2** (98-106%).  
179 3,4-DHPEA secoiridoids (**3**) isomers, **5**, **7** isomers and **9**) and *p*-HPEA secoiridoids (**4**) isomers, **6**,  
180 **8** isomers and **10**) were quantitated using the calibration curves of **1** and **2**, respectively. Secoiridoid  
181 levels, were finally expressed as mg/20 g of oil.

182

183 **Statistical Analyses.** Data were expressed as mean  $\pm$  standard deviation of triplicates. The data  
184 were statistically analysed using the statistical software Statgraphics Centurion XVI Version 16.1  
185 (Statistical Graphics, Rockville, MD). Statistically significant differences in the quantitative data of  
186 EVOO samples were evaluated by a multiple sample comparison procedure (ANOVA, Multiple  
187 Range Tests). Correlations between pair of variables (3,4-DHPEA and *p*-HPEA contents by direct  
188 and indirect methods) were assessed using Pearson's correlation coefficients (Multiple-Variable  
189 Analysis procedure, confidence level of 95%).

## 190 RESULTS AND DISCUSSION

191 **UHPLC Conditions.** Currently, the analysis of EVOO phenolic compounds in LLE or SPE extracts  
192 employ reversed-phase HPLC. The most useful solvents are acidified water, and acetonitrile,  
193 methanol or methanol/acetonitrile.<sup>1,2,16,17</sup>

194 In the present study, in order to enhance chromatographic resolution of EVOO extracts several C18  
195 columns were tested, obtaining the best results with a C18 fused-core column, which provides high  
196 column efficiency with short analysis time (results not shown), according to literature data.<sup>21,22</sup> In  
197 the selection of the mobile phase, various gradients between water and MeCN, and different  
198 modifier were tested. MeOH was excluded as organic solvent to avoid the conversion of secoiridoid  
199 aldehydic forms (**3-6**) to acetal and hemiacetal derivatives.<sup>7,19</sup> UHPLC profiles of different  
200 chromatographic conditions were recorded both with UV and HRMS detectors. Figure 2 shows the  
201 negative HRMS extracted ion chromatograms (EICs) corresponding to the main phenolic  
202 secoiridoids (**3-6**) of a EVOO sample processed by IOC procedure (extracted and reconstituted in  
203 aqueous MeOH) and analysed by UHPLC with (black lines) or without acid (red lines). In Figures  
204 3A and B are reported the corresponding UV profiles (278 nm). As can be seen, the best resolution  
205 and peak shapes were obtained with water/MeCN gradient without acid modifier (Figure 2, red  
206 lines). In acid conditions (similar profiles for 0.05 and 0.1%, v/v, of formic and acetic acids), **5**  
207 (peak 10) and **6** (peak 16) gave broadened peaks (Figures 2A and B, black lines) and produced  
208 chromatographic humps and co-elutions in the UV profile (Figure 3A), reducing the precision and  
209 the accuracy of the measurements. This fact is most likely due to equilibrium of isomeric forms of  
210 these compounds promoted in the acid conditions.<sup>22</sup> When 2 mM ammonium formate (or acetate)  
211 were used for elution, additional peaks were observed in UHPLC profiles. These were identified by  
212 HRMS as Schiff bases generated from reaction between secoiridoid aldehyde carbonyls and  
213 ammonium ion (results not shown). Thus, a gradient of water and MeCN without modifier was  
214 selected for UHPLC analysis of EVOO phenols. This gradient resulted in much more effective

215 separation of EVOO extracts, and **5** and **6** were separated into single sharp peaks (Figures 1A and  
216 B, red lines), as previously reported,<sup>23</sup> allowing their reliable quantitation in UV profile (Figure 2B).  
217 **UHPLC-HRMS/MS characterization of EVOO phenolic secoiridoids.** To date, LC-MS has been  
218 widely accepted as the main tool in identification and structural characterization of EVOO phenolic  
219 compounds. Usually, they are detected in the negative ionization mode related to a greater  
220 sensitivity,<sup>1,2</sup> nevertheless the PI mode appears to be more diagnostic for EVOO phenolic  
221 secoiridoids.<sup>1,2,24</sup>

222 In this respect, IOC extracts of two EVOO samples were analysed by UHPLC-HRMS/MS, with  
223 positive and negative ionization modes, to provide a comprehensive characterization of phenolic  
224 secoiridoids. The accurate masses, molecular formulae, typical product ions of EVOO secoiridoids,  
225 as well as of other typical EVOO phenolic compounds, are listed in Tables 1 and 2.

226 *EVOO Phenolic Secoiridoids.* Different isomers of **3** (peaks 15, 17, 18 and 21, C<sub>19</sub>H<sub>22</sub>O<sub>8</sub>) and **4**  
227 (peaks 19, 20 and 22-24, C<sub>19</sub>H<sub>22</sub>O<sub>7</sub>) were tentatively characterized according to mass (Tables 1 and  
228 2) and literature data.<sup>21</sup> **5** (peak 10, C<sub>17</sub>H<sub>20</sub>O<sub>6</sub>) and **6** (peak 16, C<sub>17</sub>H<sub>20</sub>O<sub>5</sub>) were identified by HRMS,  
229 literature data<sup>21</sup> and comparison with reference standards. The presence of **3** (C<sub>19</sub>H<sub>22</sub>O<sub>8</sub>) and **4**  
230 (C<sub>19</sub>H<sub>22</sub>O<sub>7</sub>) isomers, usually reported by LC-MS methods,<sup>21,22</sup> is justified by the elenolic acid ring  
231 opening and following equilibria between aldehydic groups, and by the presence of many  
232 oleuroside derivatives.<sup>25</sup>

233 Phenolic secoiridoids **3-6** followed in positive ionization mode all the same fragmentation pattern  
234 depending on the phenol moiety esterified (Table 2): their HRMS/MS spectra ([M+H]<sup>+</sup> ions)  
235 displayed the diagnostic product ions [CH<sub>2</sub>CH<sub>2</sub>Ph(OH)<sub>2</sub>]<sup>+</sup> (*m/z* 137.0597), for hydroxytyrosol-  
236 secoiridoids **3** and **5** (peaks 10, 15, 17, 18 and 21), and [CH<sub>2</sub>CH<sub>2</sub>PhOH]<sup>+</sup> (*m/z* 121.0648), tyrosol-  
237 secoiridoids **4** and **6** (peaks 16, 19, 20 and 22-24), given by a McLafferty-type rearrangement of the  
238 ester function.<sup>24</sup> Also, the fragmentation of corresponding [M+Na]<sup>+</sup> ions produced “marker”  
239 product ions of hydroxytyrosol (C<sub>8</sub>H<sub>8</sub>O<sub>2</sub>Na<sup>+</sup> at *m/z* 159.0417 for **3** and **5**) and tyrosol (C<sub>8</sub>H<sub>8</sub>ONa<sup>+</sup> at  
240 *m/z* 143.0467 for **4** and **6**) moieties (Table 2). As these product ions in positive MS/MS spectra

241 corresponded to the phenolic moiety of EVOO secoiridoids, they were not affected by secoiridoid  
242 isomerization or hemiacetal and acetal formation. Thus, they were suitable diagnostic ions for the  
243 characterization of hydroxytyrosol- and tyrosol-secoiridoid derivatives. Unlike, in negative  
244 ionization mode the product ions of **3-6** (Table 2) did not allow to distinguish directly the phenyl  
245 ethyl alcohol of EVOO secoiridoids, as previously reported.<sup>21</sup> Only **5** and **6** showed product ions  
246 related to phenolic part of structures ( $[\text{CH}_2\text{COOCH}_2\text{CH}_2\text{Ph}(\text{OH})_2]^-$  at  $m/z$  195.0659 and  
247  $[\text{CH}_2\text{COOCH}_2\text{CH}_2\text{Ph}(\text{OH})]^-$  at  $m/z$  179.0710, respectively) (Table 2).<sup>21,26</sup>

248 *Hemiacetal/Acetal and Monohydrate Derivatives of EVOO Phenolic Secoiridoids.* In addition to  
249 phenolic secoiridoids **3-6** (peaks 10 and 15-24), positive and negative EICs of **3-6** (Figures 2 and 4)  
250 of IOC extracts (aqueous MeOH) showed some mismatched peaks (peaks 3-9, 11, 14 and a-d),  
251 which turned out to be extraction artefacts following a careful analysis of HRMS/MS spectra. In  
252 particular, the assigned molecular formulae of base peaks in positive and negative HRMS spectra of  
253 peaks 3-9, 11, 14 and a-d were different. In their positive HRMS spectra, the base peaks  
254 corresponded to  $[\text{M}+\text{Na}]^+$  ions, as observed for secoiridoids **3-6** (Table 1). In negative ionization  
255 mode, instead,  $[\text{M}-\text{H}-\text{H}_2\text{O}]^-$  and  $[\text{M}-\text{H}-\text{CH}_4\text{O}]^-$  ions were observed as base peaks of 3-9, 11, and  
256 14 peaks on one hand and a-d peaks on the other, respectively (Table 1). The molecular formulae,  
257 assigned by positive and negative HRMS complementary data of peaks 3-9, 11, 14 and a-d, were  
258 also confirmed by accurate masses of  $[\text{M}+\text{H}]^+ / [\text{M}-\text{H}]^-$  ions present in spectra with low abundances  
259 (Table 1). These data strongly suggest that these peaks correspond to methyl-hemiacetals (**a-d**) and  
260 monohydrate forms (**7-10**) of secoiridoids **3-6** (Figure 1). Positive HRMS/MS spectra supported  
261 further the structures tentatively assigned to these secoiridoid derivatives. In fact, fragmentation of  
262  $[\text{M}+\text{Na}]^+$  ions produced always the product ions due to the loss of  $\text{H}_2\text{O}$  from **7-10** and  $\text{CH}_4\text{O}$  from  
263 **a-d** (Table 2). Likewise, dimethyl acetals of **3-6** (**e-h**) were also identified in IOC extracts (aqueous  
264 MeOH) (Figure 1). In the case of secoiridoids **5** and **6**, the identity of artefacts **9**, **10**, **a** and **c** was  
265 proved analyzing by UHPLC-HRMS the reference standards of **5** and **6** in aqueous methanol.

266 Methyl-hemiacetals, dimethyl-acetals and monohydrate forms of **5** and **6** were previously observed  
267 in EVOO by NMR<sup>7</sup> and LC-MS analysis.<sup>19</sup> Isomer peaks of methyl-hemiacetals of **5** (**a**) and **6** (**c**)  
268 (Figure 4A and B, red lines) detected in this study correspond probably to two isomers identified by  
269 NMR study of Karkoula et al.<sup>7</sup> In the case of **3** and **4**, their methyl hemiacetals (**b** and **d**), dimethyl  
270 acetals (**g** and **f**) and monohydrate forms (**7** and **8**) are reported here for the first time.

271 These UHPLC-HRMS/MS results highlight the ability of the positive ionization mode to provide  
272 more diagnostic and complete data in the characterization of EVOO phenolic secoiridoids. In  
273 addition to affording structurally significant product ions to identify the phenolic moiety  
274 ( $C_8H_8O_nNa^+$  and  $C_8H_9O_n^+$  ions in MS/MS spectra), positive ionization mode also allows  
275 identification of hemiacetal/acetal derivatives and monohydrate forms of EVOO secoiridoids **3-6**  
276 through  $[M+Na]^+$  ions. Conversely, in negative HRMS spectra the latter showed  $[M-CH_4O-H]^-$  or  
277  $[M-H_2O-H]^-$  ions with masses and molecular formulae coincident to  $[M-H]^-$  ions of the  
278 corresponding aldehydic forms (**3-6**) (Table 1). Not even the negative MS/MS spectra of **7-10** and  
279 **a-d** (Table 2) displayed useful data to differentiate hemiacetal/monohydrate derivatives from related  
280 aldehydic forms. These results suggest that the ions detected at  $m/z$  319, 303, 377 and 361 by  
281 negative LC-MS methods could correspond to both phenolic secoiridoids (**3-6**) and their  
282 hemiacetal/monohydrate derivatives (**a-d** and **7-10**). Since negative LC-MS has been usually  
283 employed in the identification and quantitative analysis of phenolic secoiridoids in EVOO extracts,  
284 false positives can be easily detected in presence of  $H_2O$  and MeOH, making the reliability of  
285 previous results more or less questionable. Thus, in LC-MS methods the positive and negative  
286 modes should be considered complementary for a correct identification and characterization of  
287 EVOO phenolic compounds.

288

289 **Formation of Hemiacetal/Acetal in Sample Preparation Procedure.** As shown in the UHPLC-  
290 UV profile of EVOO (Figure 3B), methyl-hemiacetal (**a-d**) and monohydrate **7-10** (peaks 3-9, 11,  
291 14) derivatives of secoiridoids were well detectable peaks that contributed significantly to the

292 phenolic content. Many of them were partially co-eluted with other components, ruining the  
293 separation efficiency and the precision and accuracy of quantitative results. In particular, the  
294 complete co-elution of two methyl-hemiacetals of **4 (d)** with pinoresinol (**12**) and acetoxy-  
295 pinoresinol (**13**) did not allow their correct quantitation by UHPLC-UV. Also **5** showed a poor  
296 chromatographic resolution due to the presence of a methyl-hemiacetal of **6 (c)**.

297 According to these results, the IOC sample preparation procedure was investigated in more detail,  
298 in order to prevent the formation of hemiacetal/acetal and monohydrate derivatives and,  
299 consequently, to simplify the EVOO chromatographic profile. For this purpose, two different  
300 EVOO samples were processed by the IOC procedure, replacing MeOH with MeCN in two main  
301 sample preparation steps that could potentially promote the formation of artefacts: the extraction  
302 and dissolution of extracts for UHPLC analysis.

303 When MeCN was employed in both IOC steps, the hemiacetal and acetal derivatives were not  
304 detected by UHPLC-UV-HRMS analysis (Figure 3C; blue lines in Figure 2; red lines in Figure 4).

305 Also, UHPLC-UV profile of methanolic IOC extracts reconstituted with aqueous MeCN did not  
306 reveal the hemiacetal/acetal peaks, indicating that the evaporation of MeOH restored the aldehydic  
307 forms of EVOO secoiridoids. This was also observed for **5** and **6** in previous NMR experiments.<sup>7</sup>

308 Regarding the monohydrate forms **7-10**, the peaks 3-9, 11, 14 were always observed (Figures 2-4),  
309 since the water is necessary in the sample dissolution and chromatographic eluents of reversed-  
310 phase HPLC analyses.

311 The above findings demonstrate that hemiacetal/acetal and monohydrate derivatives of EVOO  
312 secoiridoids were formed mainly in aqueous methanolic solution by the spontaneous reaction of  
313 secoiridoids with MeOH and H<sub>2</sub>O. In HPLC methods this mixture is usually employed to dissolve  
314 the EVOO phenolic extracts and these derivatives most likely were present in previous  
315 measurements reported in the literature. Thus, the use of MeCN is strongly recommended to avoid  
316 the formation of methyl hemiacetal (**a-d**) and dimethyl acetals (**e-h**) of EVOO secoiridoids.  
317 Besides, the UHPLC profile of EVOO extract in aqueous MeCN (Figure 3C) showed a less

318 complex composition than to the same extract in aqueous MeOH (Figure 3B), making easier and  
319 more accurate the quantitative measurements.

320 The conversion of hemiacetal/acetal in aldehydic forms after the evaporation of MeOH was not  
321 studied in detail, because the UHPLC-HRMS analysis of methanolic IOC extracts reconstituted  
322 with aqueous MeCN still showed methyl hemiacetals at very low levels. Hence, the use of MeCN as  
323 extraction solvent in the IOC procedure was quantitatively evaluated in order to eliminate MeOH in  
324 all steps of sample preparation. Two EVOOs with different quali-quantitative profile of secoiridoids  
325 (O-1 and O-2) were extracted by IOC procedure using MeOH/H<sub>2</sub>O and MeCN/H<sub>2</sub>O. All extracts  
326 were reconstituted with aqueous MeCN. The quantitative data (analyte/IS area ratios) of MeCN  
327 extracts were normalized to the methanolic IOC extract to determine the extraction efficiency of  
328 tested solvent. As can be seen in Figure 5, MeCN/H<sub>2</sub>O showed extraction efficiency comparable to  
329 MeOH/H<sub>2</sub>O, and no significant difference ( $p > 0.05$ ) was observed between two EVOO samples.  
330 These results proved that MeCN is a suitable solvent to extract phenolic secoiridoids from EVOO  
331 with the IOC procedure, avoiding the formation of artefacts (dimethyl acetals and methyl  
332 hemiacetals).

333

334 **Quantitative Analysis and Application to Commercial EVOOs.** Once the reliability of MeCN in  
335 the analysis of EVOO phenolic secoiridoids by IOC procedure and UHPLC-UV had been proved,  
336 the determination of the secoiridoid contents in eleven Italian EVOO samples was carried out  
337 replacing MeOH with MeCN in preparation sample steps.

338 Currently, there is no standardized analytical method for the accurate quantitative analysis of  
339 phenolic secoiridoids in EVOO, mainly due to the lack of available reference standards, in  
340 particular secoiridoids and lignans.<sup>16,27</sup> A quantitative protocol was proposed by IOC which  
341 expressed the total EVOO phenols as *p*-HPEA (**2**) equivalents, using **2** response factor against  
342 syringic acid at 280 nm for all compounds detected in UV chromatograms.<sup>17</sup> Nevertheless, standard  
343 equivalent units do not directly reflect the real content of EVOO phenolic compounds, since each



344 phenolic compound give a different response under the UV detection.<sup>16,18,27</sup> Another possible way  
345 to determine the phenolic content in EVOO is the acid hydrolysis of all the linked forms (phenolic  
346 secoiridoids) followed by the quantitative analysis of their total free forms (**1** and **2**) by LC-  
347 UV.<sup>18,20,27</sup> This method provides a rapid, simple and suitable tool to quantitate EVOO bioactive  
348 phenols and, consequently, to support the health claim. In addition, the acid hydrolysis prevents  
349 misinterpretation of the results, due to the change in profile of phenolic compounds during  
350 storage.<sup>4,18</sup>

351 On the basis these evidences, the content of **1** and **2** and their secoiridoids in Italian EVOO samples  
352 (O1-O11) was determined by UHPLC-UV analysis both in MeCN-IOC extracts (direct method) and  
353 in acid hydrolysates (indirect method). Moreover, **1** and **2** calibration curves were employed to  
354 express the quantitative results. Italian EVOO samples revealed different EVOO phenolic profiles  
355 (amount and type of the individual components), indicating the usefulness of the direct method in  
356 olive oil manufacturing process to characterize the EVOOs and to obtain complete compositional  
357 databases.

358 Table 3 summarizes the amounts of **1** and **2** derivatives and their total levels in EVOO samples,  
359 obtained with direct and indirect methods and calculated as 3,4-DHPEA (**1**) and/or *p*-HPEA (**2**)  
360 equivalents. The correlations between the quantitative data of direct and indirect methods were  
361 calculated by Pearson's coefficient ( $r$ ), considering the levels of **1** obtained after acid hydrolysis  
362 versus the sum of **1** and all secoiridoids containing the 3,4-DHPEA moiety. Similarly, the  
363 correlations were evaluated for **2** and the total EVOO phenol contents (Table 3). Very strong  
364 correlations between the two quantitative methods were observed ( $r > 0.916$ ). Moreover, no  
365 statistically differences ( $p > 0.05$ ) were observed between the **1** and **2** concentrations determined by  
366 both methods and calculated using the respective calibration curves. These findings indicate that the  
367 determination of healthy and functional EVOO phenols by the indirect method can play a useful  
368 role in routine quality control.

369 With respect to the reference standard, the use of **2** calibration curve for quantitative analysis of  
370 EVOO phenols resulted in higher levels ( $p < 0.05$ ) in comparison to those obtained using **1a**s  
371 reference standard (Table 3). O4 and O11 samples satisfied the health claim ( $\geq 5$  mg/20 g oil) only  
372 when the levels were expressed in *p*-HPEA (**2**) equivalents. Thus, the use of both reference  
373 standards is strongly recommended to furnish more accurate quantitative data. In this case (Table  
374 3), direct and indirect methods provided statistically comparable levels of total EVOO phenols ( $p >$   
375 0.05). These results are in agreement with those previously reported<sup>27</sup> and underline the need to  
376 have a simple, reproducible, and indisputable quantitative protocol. Further studies are underway to  
377 establish the reference standards and/or correction factors for the accurate determination of EVOO  
378 bioactive phenols.

379 In summary, the comprehensive investigation of chromatographic and IOC procedure conditions  
380 permitted identifying and overcoming some limitations (chromatographic resolution, peak  
381 identification and formation of secoiridoid artefacts) of the methods currently employed in the  
382 analysis of EVOO phenolic secoiridoids. The detailed UHPLC-UV-HRMS analysis revealed the  
383 presence of a large number of peaks in the chromatographic profiles of IOC extracts, characterized  
384 in depth for the first time in this study, corresponding to dimethyl acetal (**e-h**), methyl hemiacetal  
385 (**a-d**) and monohydrate (**7-10**) derivatives of **3-6** produced from the spontaneous reaction of with  
386 protic solvents (water and methanol). In particular, only positive ionization mode allowed  
387 recognition of the hemiacetal/acetal derivatives and monohydrate forms of secoiridoids, whereas in  
388 negative ionization mode these compounds can be easily mistaken with the corresponding aldehydic  
389 forms of EVOO secoiridoids. These findings emphasize the ability of positive ionization mode to  
390 provide more diagnostic and complete data, and raise questions as to the reliability of previous  
391 results obtained using negative LC-MS in the identification and quantitative analysis of phenolic  
392 secoiridoids in EVOO extracts. The study of sample preparation procedure demonstrated that the  
393 formation of hemiacetal/acetal and monohydrate derivatives occurs in aqueous methanolic solution.  
394 The use of MeCN in the IOC procedure (extraction and dissolution solvents) prevents the formation

395 of dimethyl acetals (**e-h**) and methyl hemiacetals (**a-d**) of EVOO secoiridoids, and, consequently,  
396 permits simplification of the EVOO chromatographic profile. Thus replacement of MeOH with  
397 MeCN is strongly recommended to obtain more accurate and reproducible measurements.

398 **ACKNOWLEDGMENTS**

399 We would like to express our gratitude to private partners of project. Authors contributions: R. dS.,  
400 A. P. and S. C. contributed in collecting samples and classification. A.L. P, R. C., R. dS., S. C.  
401 analyzed the state of the art. R. C. and A. P. contributed to chromatographic analysis and laboratory  
402 work, and A.L. P. supervised the laboratory work. A.L. P., R. C., L. R. and Mt. R. contributed to  
403 analysis of the data. A.L. P. and Mt. R. contributed to drafting the paper. A.L. P., R. C., L. R. and  
404 Mt. R. designed the study and contributed to critical reading of the manuscript. All the authors have  
405 read the manuscript and approved the submission.

406

407 **Funding**

408 This work was financially supported by project PON03 PE\_00090\_2 “*Modelli sostenibili e nuove*  
409 *tecnologie per la valorizzazione delle olive e dell’olio extravergine di oliva prodotto in Calabria*”  
410 and by Research Infrastructure Saf@med- *Food Safety Platform* (PONa3\_00016).

411

412 **Supporting Information.** This material is available free of charge via the Internet at  
413 <http://pubs.acs.org>.

414 HRMS/MS spectra ( $[M+H]^+$ ,  $[M+Na]^+$  and  $[M-H]^-$  ions) of EVOO phenolic secoiridoids and  
415 hemiacetal/acetal derivatives and monohydrate forms.

416 Positive and negative HRMS extracted ion chromatograms ( $[M+Na]^+$  and  $[M-H]^-$  ions) of dimethyl  
417 acetals (**e-h**) of secoiridoids **3-6** in EVOO sample processed by IOC using aqueous MeOH.

418 UHPLC-UV profiles and phenolic secoiridoid contents of 11 Italian EVOO samples.

419

420 **REFERENCES**

- 421 (1) Cerretani, L.; Gallina Toschi, T.; Bendini, A. Phenolic fraction of virgin olive oil: an  
422 overview on identified compounds and analytical methods for their determination. *Funct. Plant Sci.*  
423 *Biotechnol.* **2009**, *3*, 69–80.
- 424 (2) Bendini, A.; Cerretani, L.; Carrasco-Pancorbo, A.; Gómez-Caravaca, A. M.; Segura-  
425 Carretero, A.; Fernández-Gutiérrez, A.; Lercker, G. Phenolic molecules in virgin olive oils: a  
426 survey of their sensory properties, health effects, antioxidant activity and analytical methods. An  
427 overview of the last decade. *Molecules* **2007**, *12*, 1679–1719.
- 428 (3) Ghanbari, R.; Anwar, F.; Alkharfy, K. M.; Gilani, A. H.; Saari, N. Valuable nutrients and  
429 functional bioactives in different parts of olive (*Olea Europaea* L.) a review. *Int. J. Mol. Sci.* **2012**,  
430 *13*, 3291–3340.
- 431 (4) Servili, M.; Montedoro, G. Contribution of phenolic compounds to virgin olive oil quality.  
432 *Eur. J. Lipid Sci. Technol.* **2002**, *104*, 602–613.
- 433 (5) Covas, M. I.; de la Torre, R.; Fitó, M. Virgin olive oil: a key food for cardiovascular risk  
434 protection. *Br. J. Nutr.* **2015**, *113*, S19–S28.
- 435 (6) Pérez-Jiménez, F.; Ruano, J.; Perez-Martinez, P.; Lopez-Segura, F.; Lopez-Miranda, J. The  
436 influence of olive oil on human health: not a question of fat alone. *Mol. Nutr. Food Res.* **2007**, *51*,  
437 1199–1208.
- 438 (7) Karkoula, E.; Skantzari, A.; Melliou, E.; Magiatis, P. Direct measurement of oleocanthal  
439 and oleacein levels in olive oil by quantitative <sup>1</sup>H NMR. Establishment of a new index for the  
440 characterization of extra virgin olive oils. *J. Agric. Food Chem.* **2012**, *60*, 11696–11703.
- 441 (8) Karkoula, E.; Skantzari, A.; Melliou, E.; Magiatis, P. Quantitative measurement of major  
442 secoiridoid derivatives in olive oil using qNMR. Proof of the artificial formation of aldehydic  
443 oleuropein and ligstroside aglycon isomers. *J. Agric. Food Chem.* **2014**, *62*, 600–607.
- 444 (9) Servili, M.; Sordini, B.; Esposto, S.; Urbani, S.; Veneziani, G.; Di Maio, I.; Selvaggini, R.;  
445 Taticchi, A. Biological activities of phenolic compounds of extra virgin olive oil. *Antioxidants*

446 **2013**, 3, 1–23.

447 (10) Bernardini, E.; Visioli, F. High quality, good health: the case for olive oil. *Eur. J. Lipid Sci.*  
448 *Technol.* **2017**, 119.

449 (11) Parkinson, L.; Cicerale, S. The health benefiting mechanisms of virgin olive oil phenolic  
450 compounds. *Molecules* **2016**, 21, 1734.

451 (12) Martín-Peláez, S.; Covas, M. I.; Fitó, M.; Kušar, A.; Pravst, I. Health effects of olive oil  
452 polyphenols: recent advances and possibilities for the use of health claims. *Mol. Nutr. Food Res.*  
453 **2013**, 57, 760–771.

454 (13) Agostoni, C.; Bresson, J.; Fairweather Tait, S.; Flynn, A.; Golly, I.; Korhonen, H.; Lagiou,  
455 P.; Løvik, M.; Marchelli, R.; Martin, A. Scientific opinion on the substantiation of health claims  
456 related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333,  
457 1638, 1639, 1696, 2865), maintenance of normal blood HDL cholesterol concentrations (ID 1639),  
458 maintenance of normal blood pressure (ID 3781), “anti-inflammatory properties” (ID 1882),  
459 “contributes to the upper respiratory tract health” (ID 3468), “can help to maintain a normal  
460 function of gastrointestinal tract” (3779), and “contributes to body defences against external agents”  
461 (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA J.* **2011**, 9, 2031–  
462 2033.

463 (14) European Union Commission Regulation (EU) No 432/2012 of 16 May 2012. Establishing a  
464 list of permitted health claims made on foods, other than those referring to the reduction of disease  
465 risk and to children’s development and health. *Off. J. Eur. Union* **2012**, L136, 1–40.

466 (15) Roselli, L.; Clodoveo, M. L.; Corbo, F.; De Gennaro, B. Are health claims a useful tool to  
467 segment the category of extra-virgin olive oil? threats and opportunities for the italian olive oil  
468 supply chain. *Trends Food Sci. Technol.* **2017**, 68, 176–181.

469 (16) Hrncirik, K.; Fritsche, S. Comparability and reliability of different techniques for the  
470 determination of phenolic compounds in virgin olive oil. *Eur. J. Lipid Sci. Technol.* **2004**, 106,  
471 540–549.

- 472 (17) International Olive Council (IOC). Determination of biophenols in olive oils by HPLC;  
473 COI/T.20/Doc. No. 29, November **2009**.
- 474 (18) Purcaro, G.; Codony, R.; Pizzale, L.; Mariani, C.; Conte, L. Evaluation of total  
475 hydroxytyrosol and tyrosol in extra virgin olive oils. *Eur. J. Lipid Sci. Technol.* **2014**, *116*, 805–  
476 811.
- 477 (19) de Medina, V. S.; Miho, H.; Melliou, E.; Magiatis, P.; Priego-Capote, F.; de Castro, M. D.  
478 L. Quantitative method for determination of oleocanthal and oleacein in virgin olive oils by liquid  
479 chromatography–tandem mass spectrometry. *Talanta* **2017**, *162*, 24–31.
- 480 (20) Mulinacci, N.; Giaccherini, C.; Ieri, F.; Innocenti, M.; Romani, A.; Vincieri, F. F.  
481 Evaluation of lignans and free and linked hydroxy-tyrosol and tyrosol in extra virgin olive oil after  
482 hydrolysis processes. *J. Sci. Food Agric.* **2006**, *86*, 757–764.
- 483 (21) Vichi, S.; Cortés-Francisco, N.; Caixach, J. Insight into virgin olive oil secoiridoids  
484 characterization by high-resolution mass spectrometry and accurate mass measurements. *J.*  
485 *Chromatogr. A* **2013**, *1301*, 48–59.
- 486 (22) Suárez, M.; Macià, A.; Romero, M. P.; Motilva, M. J. Improved liquid chromatography  
487 tandem mass spectrometry method for the determination of phenolic compounds in virgin olive oil.  
488 *J. Chromatogr. A* **2008**, *1214*, 90–99.
- 489 (23) Impellizzeri, J.; Lin, J. A simple high-performance liquid chromatography method for the  
490 determination of throat-burning oleocanthal with probated antiinflammatory activity in extra virgin  
491 olive oils. *J. Agric. Food Chem.* **2006**, *54*, 3204–3208.
- 492 (24) Ryan, D.; Robards, K.; Prenzler, P.; Jardine, D.; Herlt, T.; Antolovich, M. Liquid  
493 chromatography with electrospray ionisation mass spectrometric detection of phenolic compounds  
494 from *Olea Europaea*. *J. Chromatogr. A* **1999**, *855*, 529–537.
- 495 (25) Obied, H. K.; Bedgood, D. R.; Prenzler, P. D.; Robards, K. Chemical screening of olive  
496 biophenol extracts by hyphenated liquid chromatography. *Anal. Chim. Acta* **2007**, *603*, 176–189.
- 497 (26) Di Maio, I.; Esposto, S.; Taticchi, A.; Selvaggini, R.; Veneziani, G.; Urbani, S.; Servili, M.

498 Characterization of 3, 4-DHPEA-EDA oxidation products in virgin olive oil by high performance  
499 liquid chromatography coupled with mass spectrometry. *Food Chem.* **2013**, *138*, 1381–1391.  
500 (27) Mastralexi, A.; Nenadis, N.; Tsimidou, M. Z. Addressing analytical requirements to support  
501 health claims on “olive oil polyphenols”(EC Regulation 432/2012). *J. Agric. Food Chem.* **2014**, *62*,  
502 2459–2461.  
503



504 **FIGURE CAPTIONS**

505

506 **Figure 1.** Chemical structures of phenolic secoiridoids of extra virgin olive oil.

507

508 Different isomers of compounds **3**, **4**, **7-10**, **a-d** were observed in the UHPLC profile of EVOOs.

509

510 **Figure 2.** Negative HRMS extracted ion chromatograms of (A) 3,4-DHPEA-EDA (**5**), (B) *p*-  
511 HPEA-EDA (**6**), (C) 3,4-DHPEA-EA (**3**) isomers and (D) *p*-HPEA-EA (**4**) isomers in a EVOO  
512 aqueous MeOH extract analysed with (black lines) or without (red lines) acidified gradient, and a  
513 EVOO aqueous MeCN extract (blue lines).

514

515 Mass tolerance 5 ppm; peak numbering is according to Table 1; \* corresponding to oxygenated *p*-  
516 HPEA-EDA (**6**).<sup>21</sup>

517

518 **Figure 2.** UHPLC-UV profiles (278 nm) of a EVOO aqueous MeOH extract analysed (A) with or  
519 (B) without acidified gradient, and a (C) EVOO aqueous MeCN extract.

520

521 Peak numbering is according to Table 1. EVOO sample is O2.

522

523 **Figure 3.** Positive HRMS extracted ion chromatograms of Na adducts of (A) 3,4-DHPEA-EDA (**5**),  
524 (B) *p*-HPEA-EDA (**6**), (C) 3,4-DHPEA-EA (**3**) isomers and (D) *p*-HPEA-EA (**4**) isomers (black  
525 lines) and corresponding monohydrate (blue lines) and methyl hemiacetal (red lines) derivatives in  
526 EVOO sample processed by IOC using aqueous MeOH (left) and aqueous MeCN (right).

527

528 Mass tolerance 5 ppm; peak numbering is according to Table 1; \* corresponding to oxygenated *p*-  
529 HPEA-EDA.<sup>21</sup>

530

531 **Figure 4.** Extraction efficiency of EVOO secoiridoids achieved by the IOC procedure involving  
532 aqueous MeCN as extraction solvent. Experiments performed on two EVOO samples (O1 and O2)  
533 with different quali-quantitative profiles.

534

535 Values are means of three replicates  $\pm$  standard deviation (SD). No significant differences amongst  
536 EVOO samples ( $p > 0.05$ ).

**Table 1. UHPLC-HRMS Data of Phenolic Compounds Detected in Extra Virgin Olive Oils.**

Peak No.	$t_R$ (min) <sup>a</sup>	Compound <sup>b</sup>	Molecular formula	Positive HRMS			Negative HRMS		
				$m/z$ <sup>c</sup>	ppm	Diagnostic ion	$m/z$ <sup>c</sup>	ppm	Diagnostic ion
1		3,4-DHPEA (1) <sup>b</sup>	C <sub>8</sub> H <sub>10</sub> O <sub>3</sub>	177.0524 155.0703	0.8 0.1	[M+Na] <sup>+</sup> [M+H] <sup>+</sup>	153.0557	6.8	[M-H] <sup>-</sup>
2		<i>p</i> -HPEA (2) <sup>b</sup>	C <sub>8</sub> H <sub>10</sub> O <sub>2</sub>	-			137.0610	8.6	[M-H] <sup>-</sup>
3	12.0	monohydrate 3,4-DHPEA-EDA (9)	C <sub>17</sub> H <sub>22</sub> O <sub>7</sub>	<b>361.1255</b>	-0.8	[M+Na] <sup>+</sup>	<b>319.1180</b> 337.1285	1.2 1.0	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
4	12.4	monohydrate 3,4-DHPEA-EA (7)	C <sub>19</sub> H <sub>24</sub> O <sub>9</sub>	<b>419.1307</b> 397.1486	-1.7 1.7	[M+Na] <sup>+</sup> [M+H] <sup>+</sup>	<b>377.1231</b> 395.1334	0.0 0.6	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
5	12.5	monohydrate 3,4-DHPEA-EA (7)	C <sub>19</sub> H <sub>24</sub> O <sub>9</sub>	<b>419.1304</b> 397.1489	-1.9 -1.1	[M+Na] <sup>+</sup> [M+H] <sup>+</sup>	<b>377.1231</b> 395.1334	0.0 0.7	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
6	13.0	monohydrate <i>p</i> -HPEA-EDA (10)	C <sub>17</sub> H <sub>22</sub> O <sub>6</sub>	<b>345.1303</b>	-1.6	[M+Na] <sup>+</sup>	<b>303.1230</b> 321.1336	1.0 0.9	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
a1	13.1	methyl hemiacetal 3,4-DHPEA-EDA (a)	C <sub>18</sub> H <sub>24</sub> O <sub>7</sub>	<b>375.1411</b>	-1.0	[M+Na] <sup>+</sup>	<b>319.1180</b> 351.1442	1.3 0.9	[M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
a2	13.3	methyl hemiacetal 3,4-DHPEA-EDA (a)	C <sub>18</sub> H <sub>24</sub> O <sub>7</sub>	<b>375.1408</b>	-1.5	[M+Na] <sup>+</sup>	<b>319.1179</b> 351.1440	0.8 0.5	[M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
b1	13.5	methyl hemiacetal 3,4-DHPEA-EA (b)	C <sub>20</sub> H <sub>26</sub> O <sub>9</sub>	<b>433.1462</b> 411.1649	-0.7 -0.2	[M+Na] <sup>+</sup> [M+H] <sup>+</sup>	<b>377.1230</b> 409.1487	-0.2 -1.4	M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
7	13.7	monohydrate <i>p</i> -HPEA-EA (8)	C <sub>19</sub> H <sub>24</sub> O <sub>8</sub>	<b>403.1360</b>	-0.9	[M+Na] <sup>+</sup>	<b>361.1283</b> 379.1385	0.4 0.6	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
8	13.9	monohydrate <i>p</i> -HPEA-EA (8)	C <sub>19</sub> H <sub>24</sub> O <sub>8</sub>	<b>403.1359</b>	-1.0	[M+Na] <sup>+</sup>	<b>361.1282</b> 379.1390	1.9 0.7	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
b2	14.1	methyl hemiacetal 3,4-DHPEA-EA (b)	C <sub>20</sub> H <sub>26</sub> O <sub>9</sub>	<b>433.1460</b>	-2.1	[M+Na] <sup>+</sup>	<b>377.1231</b> 409.1489	-0.1 -1.0	M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
9	14.7	monohydrate 3,4-DHPEA-EA (7)	C <sub>19</sub> H <sub>24</sub> O <sub>9</sub>	<b>419.1314</b>	0.3	[M+Na] <sup>+</sup>	<b>377.1231</b> 395.1333	-0.1 -0.9	[[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
c1	14.9	methyl hemiacetal <i>p</i> -HPEA-EDA (c)	C <sub>18</sub> H <sub>24</sub> O <sub>6</sub>	<b>359.1463</b>	-0.4	[M+Na] <sup>+</sup>	<b>303.1229</b> 335.1485	0.8 -1.1	M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
10	15.0	3,4-DHPEA-EDA (5) <sup>b</sup>	C <sub>17</sub> H <sub>20</sub> O <sub>6</sub>	<b>343.1147</b> 321.1329	-1.4 -0.1	[M+Na] <sup>+</sup> [M+H] <sup>+</sup>	319.1178	0.6	[M-H] <sup>-</sup>
c2	15.2	methyl hemiacetal <i>p</i> -HPEA-EDA (c)	C <sub>18</sub> H <sub>24</sub> O <sub>6</sub>	<b>359.1461</b>	-1.1	[M+Na] <sup>+</sup>	<b>303.1229</b> 335.1488	0.7 -0.8	M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
11	15.8	monohydrate <i>p</i> -HPEA-EA (8)	C <sub>19</sub> H <sub>24</sub> O <sub>8</sub>	<b>403.1357</b> 381.1540	-1.5 -0.9	[M+Na] <sup>+</sup> [M+H] <sup>+</sup>	<b>361.1287</b> 379.1388	0.7 0.3	[M-H <sub>2</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>
d1	16.2	methyl hemiacetal <i>p</i> -HPEA-EA (d)	C <sub>20</sub> H <sub>26</sub> O <sub>8</sub>	<b>417.1513</b>	-1.5	[M+Na] <sup>+</sup>	<b>361.1283</b> 393.1545	0.2 0.2	M-CH <sub>4</sub> O-H] <sup>-</sup> [M-H] <sup>-</sup>

12	16.2	pinoresinol <sup>b</sup>	C <sub>20</sub> H <sub>22</sub> O <sub>6</sub>	-			357.1336	1.0	[M-H] <sup>-</sup>
d2	17.2	methyl hemiacetal <i>p</i> -HPEA-EA ( <b>d</b> )	C <sub>20</sub> H <sub>26</sub> O <sub>8</sub>	<b>417.1514</b>	-1.5	[M+Na] <sup>+</sup>	<b>361.1282</b>	0.2	M-CH <sub>4</sub> O-H] <sup>-</sup>
							393.1547	0.8	[M-H] <sup>-</sup>
13	17.2	acetoxo-pinoresinol	C <sub>22</sub> H <sub>24</sub> O <sub>8</sub>	439.1362	-0.4	[M+Na] <sup>+</sup>	<b>415.1391</b>	0.8	[M-H] <sup>-</sup>
14	17.6	monohydrate <i>p</i> -HPEA-EA ( <b>8</b> )	C <sub>19</sub> H <sub>24</sub> O <sub>8</sub>	<b>403.1361</b>	-0.5	[M+Na] <sup>+</sup>	<b>361.1282</b>	0.2	[M-H <sub>2</sub> O-H] <sup>-</sup>
				381.1546	0.5	[M+H] <sup>+</sup>	379.1381	-1.8	[M-H] <sup>-</sup>
15	17.9	3,4-DHPEA-EA ( <b>3</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>8</sub>	<b>401.1205</b>	-0.6	[M+Na] <sup>+</sup>	<b>377.1231</b>	0.0	[M-H] <sup>-</sup>
				379.1386	-0.4	[M+H] <sup>+</sup>			
b3	18.1	methyl hemiacetal 3,4-DHPEA-EA ( <b>b</b> )	C <sub>20</sub> H <sub>26</sub> O <sub>9</sub>	<b>433.1464</b>	-1.1	[M+Na] <sup>+</sup>	<b>377.1231</b>	0.0	M-CH <sub>4</sub> O-H] <sup>-</sup>
				411.1650	-0.0	[M+H] <sup>+</sup>	409.1490	-0.7	[M-H] <sup>-</sup>
b4	18.4	methyl hemiacetal 3,4-DHPEA-EA ( <b>b</b> )	C <sub>20</sub> H <sub>26</sub> O <sub>9</sub>	<b>433.1462</b>	-1.5	[M+Na] <sup>+</sup>	<b>377.1230</b>	-0.1	M-CH <sub>4</sub> O-H] <sup>-</sup>
				411.1646	-0.8	[M+H] <sup>+</sup>	409.1491	-0.6	[M-H] <sup>-</sup>
16	18.6	<i>p</i> -HPEA-EDA ( <b>6</b> ) <sup>b</sup>	C <sub>17</sub> H <sub>20</sub> O <sub>5</sub>	<b>327.1200</b>	-1.0	[M+Na] <sup>+</sup>	<b>303.1230</b>	1.0	[M-H] <sup>-</sup>
				305.1281	-0.8	[M+H] <sup>+</sup>			
b5	18.9	methyl hemiacetal 3,4-DHPEA-EA ( <b>b</b> )	C <sub>20</sub> H <sub>26</sub> O <sub>9</sub>	<b>433.1465</b>	-0.9	[M+Na] <sup>+</sup>	<b>377.1229</b>	-0.5	M-CH <sub>4</sub> O-H] <sup>-</sup>
				411.1649	-0.1	[M+H] <sup>+</sup>	409.1487	-1.5	[M-H] <sup>-</sup>
b6	19.0	methyl hemiacetal 3,4-DHPEA-EA ( <b>b</b> )	C <sub>20</sub> H <sub>26</sub> O <sub>9</sub>	<b>433.1465</b>	-0.8	[M+Na] <sup>+</sup>	<b>377.1229</b>	-0.4	M-CH <sub>4</sub> O-H] <sup>-</sup>
				411.1649	-0.0	[M+H] <sup>+</sup>	409.1495	0.6	[M-H] <sup>-</sup>
17	19.3	3,4-DHPEA-EA ( <b>3</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>8</sub>	<b>401.1202</b>	-1.1	[M+Na] <sup>+</sup>	<b>377.1231</b>	0.1	[M-H] <sup>-</sup>
				379.1386	-0.4	[M+H] <sup>+</sup>			
18	19.8	3,4-DHPEA-EA ( <b>3</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>8</sub>	<b>401.1201</b>	-1.3	[M+Na] <sup>+</sup>	<b>377.1232</b>	0.2	[M-H] <sup>-</sup>
				379.1386	-0.2	[M+H] <sup>+</sup>			
19	19.9	<i>p</i> -HPEA-EA ( <b>4</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>7</sub>	<b>385.1256</b>	-0.3	[M+Na] <sup>+</sup>	<b>361.1286</b>	1.0	[M-H] <sup>-</sup>
				363.1435	-1.0	[M+H] <sup>+</sup>			
20	20.1	<i>p</i> -HPEA-EA ( <b>4</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>7</sub>	<b>385.1254</b>	-0.8	[M+Na] <sup>+</sup>	<b>361.1284</b>	0.6	[M-H] <sup>-</sup>
				363.1437	-0.4	[M+H] <sup>+</sup>			
21	20.4	3,4-DHPEA-EA ( <b>3</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>8</sub>	<b>401.1202</b>	-1.0	[M+Na] <sup>+</sup>	<b>377.1230</b>	-0.4	[M-H] <sup>-</sup>
				379.1387	-0.1	[M+H] <sup>+</sup>			
d3	20.5	methyl hemiacetal <i>p</i> -HPEA-EA ( <b>d</b> )	C <sub>20</sub> H <sub>26</sub> O <sub>8</sub>	<b>417.1515</b>	-1.0	[M+Na] <sup>+</sup>	<b>361.1283</b>	0.3	M-CH <sub>4</sub> O-H] <sup>-</sup>
				395.1698	-0.5	[M+H] <sup>+</sup>	393.1541	-0.8	[M-H] <sup>-</sup>
22	21.4	<i>p</i> -HPEA-EA ( <b>4</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>7</sub>	<b>385.1254</b>	-1.0	[M+Na] <sup>+</sup>	<b>361.1285</b>	0.8	[M-H] <sup>-</sup>
				363.1436	-0.5	[M+H] <sup>+</sup>			
23	21.5	<i>p</i> -HPEA-EA ( <b>4</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>7</sub>	<b>385.1254</b>	-0.8	[M+Na] <sup>+</sup>	<b>361.1282</b>	0.1	[M-H] <sup>-</sup>
				363.1435	-0.7	[M+H] <sup>+</sup>			
24	21.7	<i>p</i> -HPEA-EA ( <b>4</b> )	C <sub>19</sub> H <sub>22</sub> O <sub>7</sub>	<b>385.1251</b>	-1.7	[M+Na] <sup>+</sup>	<b>361.1283</b>	0.4	[M-H] <sup>-</sup>
				363.1434	-1.0	[M+H] <sup>+</sup>			

<sup>a</sup> UHPLC-UV retention times; base peaks in bold; <sup>b</sup> compared with reference standards; <sup>c</sup> in bold the base peak of HRMS spectrum.

**Table 2. Diagnostic Product Ions in Positive and Negative HRMS/MS Spectra of EVOO Phenolic Secoiridoids (3-6) and Related Methyl-Hemiacetals (a-d) and Monohydrate Forms (7-10).**

Compound	Positive HRMS/MS ( <i>m/z</i> , diagnostic ions) <sup>a</sup>	Negative HRMS/MS ( <i>m/z</i> , diagnostic ions) <sup>a</sup>
<b>3<sup>b</sup></b>	[M+Na] <sup>+</sup> : 369.0947 [M-CH <sub>4</sub> O+Na] <sup>+</sup> ; 331.0789 [M-C <sub>4</sub> H <sub>6</sub> O+Na] <sup>+</sup> ; 265.0684 [EA+Na] <sup>+</sup> ; 159.0417 [C <sub>8</sub> H <sub>8</sub> O <sub>2</sub> +Na] <sup>+</sup> [M+H] <sup>+</sup> : 347.1111 [M-CH <sub>4</sub> O] <sup>+</sup> ; 243.0854 [EA+H] <sup>+</sup> ; 225.0747 [EA-H <sub>2</sub> O+H] <sup>+</sup> ; 137.0589 [C <sub>8</sub> H <sub>9</sub> O <sub>2</sub> ] <sup>+</sup>	[M-H] <sup>-</sup> : 345.0971 [M-CH <sub>4</sub> O] <sup>-</sup> ; 307.0814 [M-C <sub>4</sub> H <sub>6</sub> O] <sup>-</sup> ; 275.0915 [M-C <sub>4</sub> H <sub>6</sub> O <sub>3</sub> ] <sup>-</sup>
<b>4<sup>b</sup></b>	[M+Na] <sup>+</sup> : 353.1000 [M-CH <sub>4</sub> O+Na] <sup>+</sup> ; 315.0842 [M-C <sub>4</sub> H <sub>6</sub> O+Na] <sup>+</sup> ; 265.0684 [EA+Na] <sup>+</sup> ; 143.0468 [C <sub>8</sub> H <sub>8</sub> O+Na] <sup>+</sup> [M+H] <sup>+</sup> : 331.1164 [M-CH <sub>4</sub> O] <sup>+</sup> ; 225.0747 [EA-H <sub>2</sub> O+H] <sup>+</sup> ; 121.0641 [C <sub>8</sub> H <sub>9</sub> O] <sup>+</sup>	[M-H] <sup>-</sup> : 291.0866 [M-C <sub>4</sub> H <sub>6</sub> O] <sup>-</sup> ; 259.0967 [M-C <sub>4</sub> H <sub>6</sub> O <sub>3</sub> ] <sup>-</sup>
<b>5</b>	[M+Na] <sup>+</sup> : 207.0631 [M-C <sub>8</sub> H <sub>8</sub> O <sub>2</sub> +Na] <sup>+</sup> ; 159.0417 [C <sub>8</sub> H <sub>8</sub> O <sub>2</sub> +Na] <sup>+</sup> [M+H] <sup>+</sup> : 303.1217 [M-H <sub>2</sub> O] <sup>+</sup> ; 137.0591 [C <sub>8</sub> H <sub>9</sub> O <sub>2</sub> ] <sup>+</sup>	[M-H] <sup>-</sup> : 195.0659 [CH <sub>2</sub> CO-3,4- DHPEA] <sup>-</sup> ; 165.0553 [M-H-3,4-DHPEA] <sup>-</sup>
<b>6</b>	[M+Na] <sup>+</sup> : 207.0631 [M-C <sub>8</sub> H <sub>8</sub> O+Na] <sup>+</sup> ; 143.0467 [C <sub>8</sub> H <sub>8</sub> O+Na] <sup>+</sup> [M+H] <sup>+</sup> : 287.1269 [M-H <sub>2</sub> O] <sup>+</sup> ; 121.0642 [C <sub>8</sub> H <sub>9</sub> O] <sup>+</sup>	[M-H] <sup>-</sup> : 179.0710 [CH <sub>2</sub> CO- <i>p</i> -HPEA] <sup>-</sup> ; 165.0553 [M-H- <i>p</i> -HPEA] <sup>-</sup>
<b>7<sup>b</sup></b>	[M+Na] <sup>+</sup> : 401.1200 [M-H <sub>2</sub> O+Na] <sup>+</sup> ; 373.1254 [M-H <sub>2</sub> O-CO+Na] <sup>+</sup>	
<b>8<sup>b</sup></b>	[M+Na] <sup>+</sup> : 385.1257 [M-H <sub>2</sub> O+Na] <sup>+</sup> ; 357.1307 [M-H <sub>2</sub> O-CO+Na] <sup>+</sup>	
<b>9</b>	[M+Na] <sup>+</sup> : 343.1151 [M-H <sub>2</sub> O+Na] <sup>+</sup>	
<b>10</b>	[M+Na] <sup>+</sup> : 327.1201 [M-H <sub>2</sub> O+Na] <sup>+</sup>	
<b>a<sup>b</sup></b>	[M+Na] <sup>+</sup> : 357.1307 [M-H <sub>2</sub> O+Na] <sup>+</sup> ; 343.1149 [M-CH <sub>4</sub> O+Na] <sup>+</sup>	
<b>b (peaks b1, b2)<sup>b</sup></b>	[M+Na] <sup>+</sup> : 401.1202 [M-CH <sub>4</sub> O+Na] <sup>+</sup> ; 373.1253 [M-CH <sub>4</sub> O-CO+Na] <sup>+</sup>	
<b>b (peaks b3-6)<sup>b</sup></b>	[M+Na] <sup>+</sup> : 401.1200 [M-CH <sub>4</sub> O+Na] <sup>+</sup>	
<b>c<sup>b</sup></b>	[M+Na] <sup>+</sup> : 327.1198 [M-CH <sub>4</sub> O+Na] <sup>+</sup>	
<b>d (peaks d1, d2)<sup>b</sup></b>	[M+Na] <sup>+</sup> : 385.1253 [M-CH <sub>4</sub> O+Na] <sup>+</sup> ; 357.1304 [M-CH <sub>4</sub> O-CO+Na] <sup>+</sup>	
<b>d (peak d3)</b>	[M+Na] <sup>+</sup> : 385.1252 [M-CH <sub>4</sub> O+Na] <sup>+</sup>	

<sup>a</sup> HRMS/MS spectra with molecular formulae and ppm are reported in supplementary material; <sup>b</sup> no differences in fragmentation patterns of isomers; EA: elenolic acid.

**Table 3. Concentrations of 3,4-DHPEA and *p*-HPEA Derivatives and their Total Levels in Italian EVOOs, Obtained with Direct (3,4-DHPEA, *p*-HPEA and Total Moieties) and Indirect (Hydrolyzed 3,4-DHPEA, *p*-HPEA and Total) Methods, Calculated as 3,4-DHPEA (1) and/or *p*-HPEA (2) Equivalents.**

Sample	O1	O2	O3	O4	O5	O6	O7	O8	O9	O10	O11	$r^d$
	mg/20 g oil (3,4-DHPEA (1) equivalents) <sup>a</sup>											
3,4-DHPEA moieties <sup>e</sup>	2.0	1.4	1.4	1.7	1.1	1.5	1.6	1.5	1.2	1.2	1.9	
<i>Hydrolysed 3,4-DHPEA</i>	2.5	1.5	1.6	1.7	0.9	1.7	1.3	1.5	1.2	1.1	2.3	0.916**
<i>p</i> -HPEA moieties <sup>f</sup>	2.9	1.7	1.4	2.5	1.4	2.0	1.8	1.6	2.4	1.6	2.6	
<i>Hydrolysed p-HPEA</i>	2.8	1.7	1.2	2.2	1.0	1.8	1.1	1.1	1.9	1.3	2.2	0.939**
Total moieties <sup>g</sup>	5.0	3.1	2.8	4.1	2.5	3.5	3.4	3.1	3.6	2.8	4.5	
<i>Hydrolysed Total</i>	5.4	3.3	2.9	3.9	1.9	3.5	2.4	2.6	3.1	2.4	4.6	0.934**
	mg/20 g oil ( <i>p</i> -HPEA (2) equivalents) <sup>b</sup>											
3,4-DHPEA moieties <sup>e</sup>	2.7	1.5	1.5	2.0	1.0	1.7	2.0	1.7	1.2	1.1	2.5	
<i>Hydrolysed 3,4-DHPEA</i>	4.1	2.3	2.5	2.6	1.3	2.6	1.9	2.3	1.7	1.5	3.7	0.916**
<i>p</i> -HPEA moieties <sup>f</sup>	4.0	1.9	1.4	3.2	1.3	2.4	2.0	1.8	3.1	1.7	3.3	
<i>Hydrolysed p-HPEA</i>	4.6	2.3	1.7	3.5	1.5	2.8	1.6	1.5	2.9	1.9	3.5	0.939**
Total moieties <sup>g</sup>	6.7	3.4	2.9	5.2	2.3	4.1	4.0	3.5	4.3	2.9	5.8	
<i>Hydrolysed Total</i>	8.6	4.6	4.2	6.2	2.7	5.4	3.6	3.8	4.7	3.4	7.2	0.934**
	mg/20 g oil (3,4-DHPEA (1) and <i>p</i> -HPEA (2) equivalents) <sup>c</sup>											
Total moieties <sup>g</sup>	6.0	3.3	2.8	4.8	2.4	3.9	3.7	3.3	4.2	2.9	5.3	
<i>Hydrolysed Total</i>	7.1	3.8	3.3	5.2	2.4	4.5	3.0	3.1	4.1	3.0	5.9	0.937**

Coefficient of variation (CV) < 11%; \*\* denote p values < 0.001; <sup>a</sup> 3,4-DHPEA (1), *p*-HPEA (2) and related secoiridoids were quantified as 3,4-DHPEA (1) equivalents; <sup>b</sup> 3,4-DHPEA (1), *p*-HPEA (2) and related secoiridoids were quantified as *p*-HPEA (2) equivalents; <sup>c</sup> 3,4-DHPEA (1), *p*-HPEA (2) and related secoiridoids were quantified using respective external calibration curves; <sup>d</sup> Pearson's coefficients between indirect and direct methods; <sup>e</sup> sum of 3,4-DHPEA (1) and secoiridoids containing 3,4-DHPEA moiety in the MeCN-IOC extracts; <sup>f</sup> sum of *p*-HPEA (2) and secoiridoids containing *p*-HPEA moiety in the MeCN-IOC extracts; <sup>g</sup> sum of 3,4-DHPEA (1), *p*-HPEA (2) and secoiridoids in the MeCN-IOC extracts.

Figure 1.





Figure 2.






**Figure 3.**

Figure 4.





Figure 5.



## Table of Contents Graphic

